Search
for
Sort by
Research 30 of 477
- When bugs and drugs conspire: driving acneiform skin toxicity
- Dermatologic Reactions to Targeted Therapy
- Management of Dermatologic Toxicities
- 26021 Delivering care for the underserved during COVID-19 through real-time teledermatology, a cross-sectional review of patients at a student-run free clinic in Dallas
- Epidermal Growth Factor Receptor Inhibitors: A Review of Cutaneous Adverse Events and Management
- Skin reactions caused by epidermal growth factor receptor inhibitors and their management
- Drug Eruptions
- Acneiform Rash Caused by an Unlikely Drug: Topiramate
- Acne and acneiform eruptions
- Urticaria, Drug Hypersensitivity Rashes, Nodules and Tumors, and Atrophic Diseases
- Drug-Induced Skin, Nail and Hair Disorders
- Lithium therapy associated with hidradenitis suppurativa: Case report and a review of the dermatologic side effects of lithium
- Dermatolojik Problemler ve COVID-19
- Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects
- Treatment of Cultured Sebocytes with an EGFR Inhibitor Does Not Lead to Significant Upregulation of Inflammatory Biomarkers
- Prevalence of Dermatologic Side Effects of Mood Stabilizers in Bipolar Disorder: A Systematic Review and A Meta-Analysis
- Taiwanese Dermatological Association consensus for the prevention and management of epidermal growth factor receptor tyrosine kinase inhibitor-related skin toxicities
- Prophylaxis and Management of Skin Toxicities
- Efficacy and safety of tofacitinib in patients with total and universal alopecia- A retrospective evaluation of 69 patients
- Cutaneous Adverse Events of Tyrosine Kinase Inhibitors in Endocrine Tumors: Clinical Features, Mechanisms, and Management Strategies
- Dermatologic adverse events associated with chemotherapy and targeted anticancer therapy
- Data from Tumor Necrosis Factor-α and Interleukin-1 Antagonists Alleviate Inflammatory Skin Changes Associated with Epidermal Growth Factor Receptor Antibody Therapy in Mice
- Cutaneous toxicities of new targeted cancer therapies: must know for diagnosis, management, and patient-proxy empowerment
- Cutaneous Toxicities of Advanced Treatment for Cutaneous Melanoma: A Prospective Study from a Single-Center Institution
- Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines☆
- Dermatologic manifestations of COVID‐19: a comprehensive systematic review
- Hair Growth After Gefitinib Treatment
- Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer
- Review article: dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel disease
- Data from Tumor Necrosis Factor-α and Interleukin-1 Antagonists Alleviate Inflammatory Skin Changes Associated with Epidermal Growth Factor Receptor Antibody Therapy in Mice